Cancer Breakthrough Pain in the Presence of Cancer-Related Chronic Pain: Fact versus Perceptions of Health-Care Providers and Patients
January 25, 2011|Hematology and Oncology
Author and Disclosure Information
Conflicts of interest: M. I. R. has served on the speaker's bureau and nurse advisory boards of Cephalon, Inc., and Meda Pharmaceuticals, Inc. She was also a clinical trial subinvestigator for Cephalon's Actiq and Fentora clinical trials and Meda/BDSI's Onsolis clinical trial. C. F. v. G. received an honorarium from Meda Pharmaceuticals, Inc., for describing the features of their buccal fentanyl product.
Correspondence to: Michelle Rhiner, RN-BC, MSN, GNP-BC, CCM, Pallgesia Associates, PO Box 8127, Alta Loma, CA 91737; telephone: (909) 319-1603; fax: (909) 945-2923
